Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.22 EPS, down 45.45% or $0.1 from last year’s $-0.12 per share.

At the moment 8 analysts are watching Halozyme Therapeutics, Inc. (NASDAQ:HALO), 3 rate it “Buy”, 4 “Outperform”, 0 “Underperform”, 0 “Sell”, while 1 “Hold”.

Looking forward, for the quarter ending Jun-16, 6 analysts have a mean sales target of 28.51 million. For the quarter ending Sep-16, 6 analysts have a mean sales target of 31.77 million whilst for the year ending Dec-16, 7 analysts have a mean target of 127.89 million.

In terms of earnings per share, 8 analysts have a -0.23 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 8 analysts have a -0.25 EPS mean target and for the quarter ending Sep-16 there are 7 estimates of -0.98 EPS.

The biggest institutional shareholders in Halozyme Therapeutics, Inc. include Third Security, LLC which owns 20 million shares in the company valued at $343.64 million. Iridian Asset Management LLC is the second biggest holder with 9 million shares currently valued at 150.50 million whilst Vanguard Group Inc has 7 million shares valued at 128.94 million.

Total shares held by institutions as of the most recent company filings are 96,848,094 with a reported 4,576,929 bought and 5,954,103 sold. These holdings make up 75.8% of the company’s outstanding shares.

Currently insiders hold 10,158,121 shares in the business which makes up 7.87% of shares. The biggest holder currently is Dr. Gregory I. Frost,PhD who owns 3,641,380 shares (2.82% of those outstanding), whilst Randal J. Kirk holds 3,538,253 (2.74% of shares outstanding) and Dr. Jonathan E. Lim,M.D. holds 710,000 (0.55% of shares outstanding).

The stock decreased 1.35% or $0.13 during the last trading session, hitting $12.09. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has fallen 47.89% over the past 6 months and is downtrending.